Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality
Recruiting
Observational Study
Intraventricular Hemorrhage
Pulmonary Hemorrhage
Death
ELGAN (22-28SA)
Bronchopulmonary Dysplasia (BPD)
Shock
Extracellular Vesicles
Enterocolitis, Necrotizing
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 0 Days – 3 Months
- Sex
- Any
- Study type
- Observational
- Participants needed
- 30 (estimated)
- Sponsor
- University Hospital, Montpellier · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to understand the role of extracellular vesicles (EVs) in extremely premature infants, those born before 28 weeks of gestation. EVs are tiny particles released by cells that carry important information about the body's condition. In extremely premature infants, blood vessels may not function properly, leading to serious health problems such as bleeding in the brain, lung injury, or…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Mother over 18 years old, able to speak and understand French
* Newborn less than 28 weeks of gestation, born and hospitalized at Montpellier University Hospital
* Umbilical cord venous blood collected immediately after birth (from the segment between the cord clamp and the pl…
Contacts
No contact information available.